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Abstract 42 
Background Immunity declines with age that leads to re-activation of varicella zoster virus 43 
(VZV). In humans, age associated immune changes are usually measured in blood leukocytes 44 
however this may not reflect alterations in tissue-specific immunity. 45 
Objectives We used a VZV antigen challenge system in the skin to investigate changes in 46 
tissue specific mechanisms involved in the decreased response to this virus during ageing.  47 
Methods We assessed cutaneous immunity by the extent of erythema and induration after 48 
intradermal VZV antigen injection. We also performed immune histology and transcriptomic 49 
analyses on skin biopsies taken from the site of challenge in young (<40 yrs) and old (>65 yrs) 50 
subjects. 51 
Results Old humans exhibited decreased erythema and induration, CD4+ and CD8+ T cell 52 
infiltration and attenuated global gene activation at the site of cutaneous VZV antigen challenge 53 
compared to young subjects. This was associated with elevated sterile inflammation in the skin 54 
in the same subjects, related to p38 MAPK-related pro-inflammatory cytokine production (p 55 
<0.0007).  We inhibited systemic inflammation in old subjects by pre-treatment with an oral 56 
small molecule p38 MAP kinase inhibitor (Losmapimod), which reduced both serum C reactive 57 
protein (CRP) and peripheral blood monocyte secretion of IL-6 and TNF-α. In contrast, 58 
cutaneous responses to VZV antigen challenge was significantly increased in the same 59 
individuals (p <0.0006).  60 
Conclusion Excessive inflammation in the skin early after antigen challenge retards antigen-61 
specific immunity. However this can be reversed by inhibition of inflammatory cytokine 62 
production that may be utilized to promote vaccine efficacy and the treatment of infections and 63 
malignancy during ageing.    64 
 65 
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Key Messages: 66 
1) Cutaneous immunity to VZV decreases during ageing 67 
2) Associated with excessive early skin inflammatory response  68 
3) The inflammation is linked to p38 MAP kinase activation 69 
4) An oral p38 inhibitor (Losmapimod) inhibits systemic inflammation 70 
5) Short-term p38 treatment enhances the VZV skin response in old subjects  71 
 72 
Capsule summary: Elevated cutaneous inflammation retards VZV-specific immunity. Inhibiting 73 
inflammatory cytokine production with p38 MAPkinase inhibitors enhances VZV-specific 74 
cutaneous immunity. Targeting inflammation may be used to promote vaccine efficacy and the 75 
treatment of malignancy during ageing. 76 
 77 
Keywords: Ageing; p38 MAP kinase; VZV; inflammation 78 
 79 
Abbreviations: 80 
CBA – cytometric bead array 81 
CRP - C reactive protein 82 
DC – Dendritic cell 83 
DEG - Differentially-expressed genes 84 
DTH – Delayed type hypersensitivity 85 
GSVA - Gene set variation analysis 86 
IL – Interleukin 87 
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PV – perivascular infiltrate 88 
TNF – Tumour necrosis factor 89 
TRM – Resident memory T cells 90 
VZV – Varicella Zoster Virus  91 
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Introduction: 92 
Older individuals have reduced immune function that predisposes them to an increased 93 
incidence of infection and malignancy(1, 2).  In addition, vaccine efficacy against many 94 
pathogens is also reduced in these subjects(3). We developed a human experimental system to 95 
investigate antigen-specific immunity in vivo where healthy volunteers are challenged 96 
intradermally to induce antigen-specific delayed type hypersensitivity (DTH) responses. This 97 
enabled the investigation of the kinetics and the specificity of memory T cell expansion, and the 98 
interactions between different leukocytes after a single episode of immune stimulation in situ(4-99 
6).   100 
VZV is an alpha-herpes virus that causes chickenpox. After resolution of the initial infection VZV 101 
becomes latent within dorsal root ganglia but re-activates in older subjects causing herpes 102 
zoster (shingles)(7, 8). During both primary infection and latent virus reactivation the absence of 103 
T cell immunity results in VZV-induced pathology(9, 10). Therefore, decreased responsiveness 104 
to VZV challenge in aged skin is a good model for investigating immune decline during.  105 
  106 
Old individuals exhibited reduced erythema and induration (clinical response) after injection of a 107 
VZV skin test antigen that was correlated with decreased T cell infiltration and proliferation in 108 
the skin. This was not due to defective macrophage activation(4) or reduced inherent function of 109 
skin resident memory T cells (TRM)(11). On the contrary, we identified a propensity of the skin of 110 
old but not young subjects to mount an over-exuberant pro-inflammatory response upon sterile 111 
challenge with a physiological saline solution. This was significantly inversely correlated with 112 
decreased VZV antigen responsiveness in the same individuals.  113 
 114 
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Previous studies demonstrated that systemic inflammation, indicated by elevated levels of 115 
serum IL-6, TNFα, and CRP, are strong predictors for frailty and mortality during ageing(12, 13). 116 
Ingenuity Pathway Analysis indicated a significant association between the inflammatory gene 117 
in the skin in old subjects with p38 MAP kinase pathway activation (p value of 1 x 10-18).  We 118 
tested the hypothesis that the magnitude of sterile pro-inflammatory response in the skin and 119 
reduced antigen-specific immunity in the same individuals was linked. To do this we treated old 120 
humans with the oral p38 MAP kinase inhibitor, Losmapimod, for 4 days to inhibit pro-121 
inflammatory cytokine production. This resulted in a significant reduction of CRP and peripheral 122 
blood monocyte secretion of IL-6 and TNF-α after stimulation in vitro but significantly increased 123 
response to cutaneous response to VZV antigen challenge in the same individuals. Therefore, 124 
decreased VZV antigen challenge responsiveness in the skin of old subjects is related to 125 
excessive pro-inflammatory responses. Therefore, anti-inflammatory intervention may be a 126 
strategy for boosting cutaneous immunity during ageing.  127 
  128 
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Materials and Methods 129 
Study design: 130 
This work was approved by the Ethics Committee Queen’s Square (London) and by institutional 131 
review board (UCL R&D). Healthy young individuals <40 years (n=97; median age, 29 years) 132 
and old individuals >65 years (n=78, median age, 75.5 years) were recruited (Supplementary 133 
table 1, Supplementary table 2). Exclusion criteria are described in the online methods section.. 134 
All volunteers provided written informed consent and study procedures were performed in 135 
accordance with the principles of the declaration of Helsinki.  136 
Skin tests: VZV antigen (BIKEN, The Research Foundation for Microbial Diseases of Osaka 137 
University, Japan) was injected intradermally into sun unexposed skin of the medial proximal 138 
volar forearm as per manufacturer’s instructions. Induration, palpability, and the change in 139 
erythema from baseline were measured and scored on day 3 as described previously(14). A 140 
clinical score (range 0-10) based on the summation of these parameters was then 141 
calculated(14). The injection site was sampled by skin biopsy at the different times after 142 
injection with VZV skin test antigen.  143 
Losmapimod treatment: A sub group of 18 old volunteers (8 males, 10 females, age range 65-144 
77:  median age 69) were subjected to VZV antigen skin testing as described above.  145 
Approximately 2-3 months later volunteers received 15 mg Losmapimod (GW856553) BID for 4 146 
days (provided by Glaxo-Smith-Klein under a Medical Research Council Industrial Collaboration 147 
Agreement). The Losmapimod 15 mg BID dose used in this study was chosen on the basis of 148 
the PK, PD and safety profiles of Losmapimod observed in GSK Phase I and II studies(15).   149 
On day 4 of after Losmapimod treatment VZV skin test antigen was injected intradermally and 150 
clinical score recorded 48h later, as before. History of liver disease or elevated liver 151 
transaminases (>1.5 times the upper limit of normal) and abnormal ECG were additional 152 
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exclusion criteria for this part of the study. Serum CRP levels were measured using a high 153 
sensitivity assay (16). To assess compliance, ex vivo whole blood LPS-stimulation assays were 154 
performed before and 4 day after Losmapimod treatment(17). Briefly, peripheral blood was 155 
cultured with LPS (0-1 mg/ml) for 24 h (37oC, 5% CO2).  Levels of TNF-α and IL-6 in plasma 156 
were assessed by cytometric bead array (CBA, BD). 157 
Skin biopsies: Punch biopsies (5 mm diameter) from the site of antigen injection were obtained 158 
from young and old volunteers at various time-points (as indicated) post-VZV skin test antigen 159 
injection. Control skin punch biopsies from normal (un-injected) forearm skin were also 160 
obtained. Biopsies were frozen in OCT (optimal cutting temperature compound; Bright 161 
Instrument Company Ltd) as described(4, 11). 6µm sections were cut and left to dry overnight 162 
and then fixed in ethanol and acetone and stored at -80ºC. 163 
Immunohistochemistry: Skin sections from normal, VZV skin test antigen or saline injected 164 
skin were stained with optimal dilutions of primary antibodies as described(4, 11) 165 
(Supplementary Table 3). The number of positively stained cells per mm2 was counted manually 166 
using computer-assisted image analysis (NIH Image 6.1; http://rsb.info.nih.gov/nih-image). Cell 167 
numbers were expressed as the mean absolute cell number counted within the frame.   168 
Immunofluorescence: Sections were stained with optimal dilutions of primary antibodies and 169 
followed by an appropriate secondary antibody conjugated to various fluorochromes as 170 
described(4, 11) (Supplementary Table 4).  The number of cells in 5 of the largest perivascular 171 
infiltrates present in the upper and mid dermis were selected for analysis and an average was 172 
calculated(18). Macrophage images were imaged on the AxioScan Z1 slide scanner and 173 
Imaged on Zen Blue (Zeiss, Cambridge U.K.)  174 
Skin Biopsy digestion for flow cytometric analysis: Skin biopsies (5 mm) were taken from 175 
normal and saline injected skin (6 h post-injection) and disaggregated by overnight incubation 176 
(37oC; 5% CO2) in 0.8 mg/ml collagenase IV (Sigma Aldrich) with 20% FCS. Single cell 177 
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suspensions were obtained by filtering the suspension through 100, 70 and 40 µm filters. Cells 178 
derived from skin biopsies were assessed by flow cytometric analysis on a BD Fortessa using 179 
FACSDIVA software (BD Biosciences), and subsequently analysed using FlowJo Version X 180 
(Treestar, Ashland, U.S.A). For details off antibodies used see Supplementary Table 5.  181 
Cytometric Bead Array (CBA): IL-6, IL-8 and TNFα plasma concentrations were measured by 182 
CBA assay (BD), according to the manufacturer’s protocol. The lower limit of detection for each 183 
analyte was 1.5 pg/ml. 184 
Transcriptional analyses: 3 mm punch biopsies were collected from the injection site 6 or 72 h 185 
post injection with VZV antigen or normal saline,  immediately frozen in RNAlater. Normal (un-186 
injected) skin from the same site was collected as a control from each volunteer. Frozen tissue 187 
was homogenized and total RNA was extracted from bulk tissue homogenates using RNeasy 188 
Mini Kit (Qiagen). Details of gene expression analyses are in the online methods.  189 
Where indicated, the human skin-punch microarray data were combined with a large collection 190 
of other primary cell gene-expression data sets (745 individual microarray data sets), available 191 
from the GEO database on the same Affymetrix Human Genome U133 Plus 2.0 expression 192 
array platform.  The entire collection of primary cell expression data are available via the GEO 193 
accession number: GSE49910.  Full details of each primary cell data set have been 194 
published(19). Upstream regulator analysis was performed with Ingenuity Pathway Analysis 195 
(Qiagen). 196 
 197 
Statistics: Statistical analysis was performed using GraphPad Prism version 6.00 (GraphPad 198 
Software, San Diego, California, USA).  Paired or unpaired t-test were used when data were 199 
normally distributed and non-parametric tests were utilised when data were not normally 200 
distributed. The Kruskall-Wallis test was used to compare three or more unpaired groups and a 201 
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2-tailed Mann-Whitney test was used when comparing only two unpaired groups. The Wilcoxon 202 
matched pairs test was used when comparing two groups of matched data. Two way ANOVA 203 
was used to compare the effects of Losmapimod and LPS.  204 
  205 
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Results: 206 
Decreased response to VZV challenge in the skin during ageing   207 
We investigated the cutaneous response of young (<40 yrs) and old (>65 yrs) volunteers to VZV 208 
antigen skin challenge. All volunteers had a prior history of chickenpox. At 72 hrs after VZV 209 
injection, young subjects had obvious erythema and induration (clinical responses), whereas the 210 
clinical response of old subjects was significantly lower and correlated inversely with increasing 211 
age (Fig. 1A, p<0.0001, n=184, young n=97; old n=78, middle age 40-65 n=14, Supplementary 212 
figure 1; for participant details see Supplementary Table 1, 2).  There were no differences in the 213 
response of male and female donors in young and old age groups (p = 0.5, Supplementary 214 
table 2). The decrease in clinical score was associated with decreased CD4+ T cell 215 
accumulation at the site of VZV challenge in the skin at all time points investigated (Fig 1B,C,D). 216 
There was a highly significant correlation between the clinical score (measured at 72hrs) and 217 
the extent of CD4+ T cell accumulation and old subjects (measured at 7 days; Fig. 1E). We 218 
stratified old individuals into those who had a low skin response to VZV (clinical score of <4; 219 
88% of old volunteers) and those who showed similar responses to young subjects with a 220 
clinical score >4 (86% of young volunteers).  221 
The decreased cutaneous response to VZV in old donors was not related to differences in the 222 
number of resident memory CD4+ or CD8+ T cells defined by expression of CD69 alone or the 223 
combination of CD69 and CD103(20, 21) in the skin of young and old individuals(11) 224 
(Supplementary Fig. 2).  225 
 226 
Reduced Dendritic cell/ T cell interaction and T cell proliferation after VZV challenge in 227 
old individuals 228 
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Immune clusters containing both antigen presenting cells and T cells (referred to as skin 229 
associated lymphoid tissue) are generated in the skin during cutaneous immune responses(22). 230 
A highly significant increase in the number of CD11c+ DCs was observed in the skin of young 231 
but not old individuals at different times after VZV antigen challenge (Fig. 2A,B).  Dendritic cells 232 
accumulate around blood vessels and form large perivascular clusters with CD4+ T cells (Fig. 233 
2C) and to a lesser extent CD8+ T cells (not shown). By 3 days after VZV antigen challenge the 234 
majority of the DCs within these infiltrates in the skin of young individuals were CD1c-negative 235 
and expressed DC-LAMP, a marker of mature inflammatory DCs. In the skin of old individuals 236 
after VZV antigen challenge, DC infiltration was significantly reduced compared to the young 237 
group (Fig. 2A,B).  238 
 239 
In young individuals, proliferating (Ki67+) CD4+ T cells were undetectable in normal skin but a 240 
significant increase was observed from 3 days post-VZV antigen challenge compared to 241 
baseline (Supplementary Fig 3A, B). Proliferation of CD8+ T cells was also observed but to a 242 
lesser extent than in CD4+ T cells (Supplementary Fig. 3 C, D).  In contrast, in the skin of old 243 
individuals CD4+ and CD8+ T cell proliferation was extremely low even after 7 days of VZV 244 
antigen challenge (Supplementary Fig. 3). This indicates that in young subjects, the increased 245 
accumulation of T cells in the skin after VZV antigen challenge occurs in part from their 246 
proliferation at the site of injection.   247 
 248 
We investigated whether decreased endothelial cell activation contributed to the reduced T cell 249 
infiltration in the skin of old subjects. At 6 h after VZV antigen injection, 20% of the CD31+ 250 
capillary loops in young and old skin expressed both E-selectin and VCAM-1, that was 251 
significantly higher than the expression observed in unchallenged (Day 0) skin from either age 252 
group (Supplementary Fig. 4). This suggests that endothelial cells in old individuals are not 253 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14
defective and can be activated to the same extent as young subjects early in the response. At 254 
later time points, capillary loops in young individuals showed significantly increased expression 255 
of E-selectin when compared to old individuals (Supplementary Fig. 4). Therefore, reduced 256 
response to VZV antigen challenge was not due to defects in the initiation of the response, but 257 
was related to either active inhibition and/or lack of immune amplification at later stages. 258 
 259 
Global decrease in the magnitude of gene expression in the skin following VZV challenge 260 
in old individuals  261 
We next performed global gene expression analyses to identify genes that may be associated 262 
with the decreased response to VZV antigen challenge in old subjects.  In each young or old 263 
donor, skin punch biopsies were taken from the site of either VZV antigen challenge (6h and 264 
72h post-injection) or saline injection (6h and 72h post-injection; control) in the contralateral arm 265 
of the same individual (resulting in a total of 4 biopsies per individual). The gene expression was 266 
compared to the signature in biopsies taken for normal, un-injected skin from 6 young and 9 old 267 
donors (Fig. 3). In a previous study we showed that there was no evidence for inflammatory 268 
responses in either group at steady state(11).    269 
Six hours post-VZV antigen challenge there were 935 significantly up-regulated and 1042 down-270 
regulated genes in the skin of young individuals and 820 up-regulated and 550 down-regulated. 271 
genes in the old group (Supplementary Fig. 5A). Although similar pathways were activated in 272 
the skin of young and old individuals at 6 hours after VZV antigen challenge, the magnitude of 273 
their expression was reduced in the old group (Supplementary Fig. 5B, 5C). At 72h after VZV 274 
antigen challenge, young individuals exhibited a strong transcriptional response that was 275 
considerably reduced in the old group (>5000 differentially-expressed genes (DEG) in young, 276 
666 DEG in the old, Fig. 3A,B).  The top 30 genes that are significantly differentially expressed 277 
are shown in Fig. 4B, indicating that the same genes are upregulated in the both groups but that 278 
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the expression was reduced in the old subjects, indicating attenuated immune amplification.  279 
Genes associated with T cell and DC activation including ITGAX (which encodes CD11c), CD2, 280 
CD28, CD69, CD83, CD86, EOMES, ICOS, and STAT1 were more highly expressed in the skin 281 
at 72 hrs of VZV challenge in young compared to the old group (Supplementary Table 6). There 282 
was activation of signalling pathways associated with immune responses, inflammation, and 283 
immune response to viruses, and pathways induced by type I IFN and IFN-γ signalling in young 284 
but not old individuals (Supplementary Fig. 5). 285 
 286 
Saline injection induces an inflammatory response in old donors which inversely 287 
correlates with cutaneous VZV response 288 
Sterile saline solution was a physiological control that was injected into to the contralateral arm 289 
of the same individuals who received VZV skin antigen challenge (Fig 4A). In young individuals, 290 
saline injection had a negligible effect on gene expression compared to normal skin (Fig. 4A, B; 291 
30 DEG at 6 hrs post injection). However, in old subjects, saline injection induced significant 292 
early expression of numerous inflammatory genes (Fig. 4A, B; 856 DEG, FDR<0.05; FCH>2, 293 
Supplementary Table 7) including IL6, CXCL8 and PTX3 and also genes indicative of myeloid 294 
cell activation including CXCL2, IL1B, ICAM1 and FCGR3A (Fig. 4B; Supplementary Table 7). 295 
 296 
Using Ingenuity Pathway Analysis we found a significant association with predicted p38 MAP 297 
kinase  pathway activation (p value of 1 x 10-18) when the genes that were upregulated after 298 
saline injection (6 hours) in old skin were compared to unchallenged control old skin.  The 299 
majority of the top 30 genes activated after 6 hours saline injection (Fig, 4C; indicated by 300 
asterisk) are induced by p38 MAP kinase signalling or are regulators of p38 MAP kinase 301 
activation. Pathway analysis further suggested that the response to saline in the skin of old 302 
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subjects involved the activation of inflammatory pathways relating to Type I IFN production, 303 
TNF-α signalling, MAP kinase activation, IFN-γ responses and IL-17 production (Fig. 4D).  304 
Principal component analysis demonstrated that gene expression in response to saline injection 305 
in young and old individuals was distinct (Supplementary Fig. 6B) and that a large number of the 306 
genes which were upregulated by 6 h after saline injection in old skin were also induced by VZV 307 
antigen challenge at the same time point (Fig. 4C, Supplementary Fig. 6). These data indicate 308 
that the early transcriptional response to VZV antigen challenge in the skin of old subjects 309 
includes an inflammatory component that may not be specific for the antigen itself.  310 
 311 
We investigated if the propensity to exhibit sterile inflammatory responses at 6 hours after 312 
nonspecific (saline-induced) inflammation in ageing skin was associated with decreased clinical 313 
response to VZV challenge in the contralateral arm of the same individuals at 48 hours.  To 314 
address this, the expression levels of 384 genes designated as positive regulators of 315 
inflammatory response (Supplementary Table 8) were compared in the skin of young and old 316 
individuals (n=10 old, n=6 young) at 6 h after saline injection. Using GSVA analysis each 317 
individual was assigned a numerical score (denoted as inflammatory index) based on the 318 
variation in expression of all these inflammatory genes.  A highly significant inverse correlation 319 
was observed when the inflammatory index value to saline injection for each individual was 320 
plotted against the clinical response to intradermal VZV antigen challenge in the contralateral 321 
arm (Fig. 4E).  A similar, significant inverse correlation was observed between the expression 322 
level of IL-1β, IL-6, IL-12p35 and IL-12p40 as determined by qRT-PCR and an individual’s 323 
clinical response to VZV antigen challenge were compared (Supplementary Fig 7). This 324 
indicates an association between propensity to exhibit early sterile inflammation and reduced 325 
responses to VZV antigen challenge in the skin of the same old subjects in vivo.  326 
 327 
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Non-specific inflammation induced by saline injection is associated with mononuclear 328 
phagocytes 329 
In order to identify the cell type which may contribute to the elevated pro-inflammatory response 330 
to saline injection in ageing skin, the DEG identified at 6 h after saline-injection (FDR<0.05; 331 
FCH>2, Table S2) were imported into BioLayout Express3D (see methods; Fig. 5A).  332 
Comparison of the mean cellular expression profiles of the gene clusters derived from this 333 
network graph suggested that many of the genes within them were strongly associated with 334 
cells of the monocyte/macrophage lineage (Fig. 5A, Supplementary Table 9). Furthermore, 335 
immunohistological analysis also demonstrated a significant increase in the number of CD163+ 336 
mononuculear phagocytes in the skin of old subjects within 6h of saline injection (Fig. 5B,C). 337 
This was confirmed by multi-parameter flow cytometry where we identified significantly 338 
increased proportions of HLA-DR+CD14+ mononuclear phagocytes in old compared to young 339 
skin biopsies 6h after saline injection (Fig.  5D and Supplementary Fig 8). This rapid increase in 340 
the frequency of CD14 expressing mononuclear phagocytes was probably a result of 341 
recruitment from the blood as these cells were not in cycle (not shown)(23). The increase in 342 
“inflammatory” monocytes in old subjects was transient and coincided with the transient sterile 343 
inflammatory response that was only observed at 6 h but not 24 h after saline injection.  A 344 
similar significant transient increase in mononuclear phagocytes is observed when old 345 
individuals were injected with VZV (Supplementary Fig 4E). 346 
 347 
Short-term p38 MAP kinase-blockade improves clinical response to VZV skin challenge 348 
in older individuals 349 
We tested the hypothesis that excessive pro-inflammatory cytokine secretion that is driven by 350 
p38 MAP kinase signalling in mononuclear phagocytes early in the skin response. To do this we 351 
treated 18 healthy old volunteers who had a low previous skin response to VZV challenge 352 
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(clinical score <4) with Losmapimod, a potent and selective oral p38 MAP kinase inhibitor, 353 
before VZV antigen re-challenge in the skin(16, 24) (Fig 6A). These individuals were 354 
investigated 2-3 months after the first skin test and were pre-treated with the drug for 4 days 355 
before re-challenge with VZV antigen in the skin.  In parallel studies we showed that the re-356 
challenge of old volunteers with VZV skin test antigens did not significantly boost their original 357 
clinical score (n=14, p=0.58, Supplementary  Fig. 9).  358 
 359 
CRP production in the liver is upregulated by p38 MAP kinase-dependent cytokines such as IL-360 
1 and IL-6(25, 26). Serum CRP was significantly reduced after Losmapimod pre-treatment (Fig. 361 
6B, p=0.04, n=18). In addition, TNFα, IL-6  and IL-8 production by LPS-stimulated PBMCs from 362 
the same donors was also significantly reduced after Losmapimod pre-treatment (Fig. 6C, 363 
Supplementary Fig 10). In contrast, Losmapimod pre-treatment significantly enhanced the 364 
clinical response to VZV antigen challenge in the skin of 13 of 18 old subjects (Fig. 6D, n=18, 365 
p=0.0006). This increase in clinical score to VZV challenge correlated with the decrease in CRP 366 
in the serum in the same individuals (Fig 6E). Losmapimod pre-treatment had no effect on CD4+ 367 
or CD8+ T cell function in response to CD3 and IL-2 stimulation in the same donors as defined 368 
by cytokine expression (IFNγ, IL-2 and TNFα) or proliferation as defined by Ki67 expression 369 
(Supplementary Fig 10). Histological assessment of biopsies collected from 4 old subjects who 370 
showed an increased clinical response after Losmapimod treatment showed that there was a 371 
significant increase in the number of CD11c+ DCs in the perivascular infiltrates (p=0.04) that 372 
were associated with increased numbers of CD4+ T cells in immune clusters (representative 373 
experiment shown in Fig. 6F, top and bottom right panels). These clusters were not found in 4 of 374 
the individuals who did not respond to Losmapimod treatment (Fig. 6F top and bottom left 375 
panels). These clusters resembled those found after VZV challenge of skin in young subjects 376 
(see Fig. 2). This shows that p38 MAP kinase inhibition significantly reduced pro-inflammatory 377 
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responses and that this was associated with enhancement of antigen-specific immune 378 
responses in the skin of old individuals in vivo. 379 
380 
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Discussion 381 
The cutaneous recall response to intradermal antigen challenge is a manifestation of immune 382 
memory and this reaction decreases with age(4, 27-29).  We have investigated reasons for this 383 
decrease in order to explain the increased incidence of cutaneous infection and malignancy 384 
during ageing(2, 30).  Early inflammation (erythema and induration, 48 hours)  is required to 385 
initiate the cascade of events leading to optimal cellular infiltration in the skin that occurs later 386 
(peak at 7 days)(14). An unexpected observation therefore was that excessive inflammation 387 
during the early phase after VZV challenge hinders the amplification of the response in old 388 
subjects. The response to VZV in older individuals is not inhibited from the outset since the 389 
endothelium of old and young subjects are activated equally at 6 h and gene expression at this 390 
time is similar.  Furthermore, the decreased response after VZV antigen challenge in these 391 
individuals was not due to intrinsic changes in the functionality of cutaneous TRM cells or 392 
macrophages since these cells from both age groups were equally responsive when isolated 393 
from skin and activated in vitro(4, 11).  394 
 395 
In other studies, elevated systemic inflammation has been shown to have a negative impact on 396 
the cutaneous recall response to candida antigens (31), however this study did not investigate 397 
the response of old subjects or events that occur in the skin itself. The reduced efficacy of 398 
vaccination has also been linked to excessive inflammation for influenza(32), yellow fever(33), 399 
tuberculosis(34) and Hepatitis B vaccines(35). Furthermore, inflammatory macrophages in 400 
patients with chronic artery disease suppress T cell activation and expansion in vitro and this is 401 
associated with defective VZV-specific T cell immunity in the peripheral blood of these 402 
patients(36). The proposed mechanism for this inhibition involves the upregulation of the 403 
inhibitory receptor ligand PD-L1 on the inflammatory macrophages that inhibit function of PD1 404 
expressing T cells(36). This suggests that the infiltration of inflammatory monocytes that 405 
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express PD-L1 during sterile inflammation may block early activation of cutaneous resident 406 
memory T cells (TRM) since this latter population expresses significantly higher levels of PD-1 407 
during ageing(11).  408 
 409 
Type I IFN has been shown to interfere with antigen-specific T cell responses and excessive 410 
levels of these mediators impair the clearance of both viral and mycobacterial infections in mice 411 
in vivo(37, 38). In the present study we also found a strong type I IFN signature in the skin of old 412 
subjects after saline injection although other inflammatory pathways were also upregulated. The 413 
impact of excessive inflammation on the inhibition of antigen-specific T cell function is 414 
particularly important for ageing since older individuals have widespread low grade systemic 415 
inflammation termed “inflammageing”(12) that is linked to expression of inflammasome gene 416 
modules that may underpin clinical frailty and immune dysfunction(13).  417 
 418 
It is not clear why saline injection induces an early but transient inflammation in the skin of old 419 
individuals (observed at 6 h but not at 24 h after injection).  However, NaCl itself is pro-420 
inflammatory and has been shown to induce Th17 cells whilst conversely inhibiting Foxp3+ Treg 421 
function(39, 40) and to also activate inflammatory cascades in monocytes and bone-marrow 422 
derived macrophages in vitro(41, 42). The saline control that we used in the current study 423 
contained 0.9% NaCl, which is similar to the concentration used in the diluent of the VZV skin 424 
test antigen (0.68% NaCl). Therefore a component of the transcriptional response of old 425 
subjects to VZV antigen would also include a response to NaCl in the diluent that may hinder 426 
the induction of antigen-specific immunity in old subjects. This response is not observed in 427 
young subjects. We identified mononuclear phagocytes as the source of the saline-induced 428 
cutaneous inflammation.  429 
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 430 
Many of the inflammatory mediators induced by saline injection in older subjects were linked 431 
directly or indirectly to the activation of the p38 MAP kinase pathway. Many pharmaceutical 432 
companies have generated small molecule p38 MAP kinase inhibitors in humans in vivo in 433 
phase I,II and III trials to block inflammatory diseases/disorders(43). Although most trials with 434 
p38 MAP kinase inhibitors were discontinued because of hepatotoxicity after long term 435 
treatment (>3 months) and adaptation of cell-signalling  pathways leading to reduced drug 436 
efficacy(44), these inhibitors do not show evidence of toxicity in the short-term (weeks) in 437 
humans in vivo.  We therefore treated old subjects who were not responsive to cutaneous VZV 438 
antigen challenge with Losmapimod (GW856553), a selective, reversible, competitive inhibitor 439 
of p38 MAP kinase, to test the hypothesis that reducing inflammation in the skin would enhance 440 
antigen-specific cutaneous immunity. The key observation was that Losmapimod pre-treatment 441 
significantly enhanced the cutaneous response to VZV in older subjects. Although our previous 442 
studies have shown that that p38 inhibition can enhances T cell proliferation in vitro(45-47), in 443 
the current study Losmapimod treatment did not affect peripheral blood T proliferation or 444 
cytokine production after stimulation CD3/IL-2. Thus the enhancement of cutaneous immunity is 445 
likely to be due to the anti-inflammatory effects of the drug. 446 
 447 
This raises the question of whether the short-term inhibition of p38 MAP kinase signalling and/or 448 
inhibition of inflammation would also enhance immunity in other tissues. An interesting 449 
possibility is that this would be a strategy to improve vaccine efficacy that is decreased in 450 
ageing individuals(3, 48). Another point to consider is that increasing the strength of adjuvants 451 
to enhance vaccine responses during ageing may be counter-productive if they further increase 452 
inflammatory responses and it may be important to stratify old vaccinees on the basis of their 453 
baseline inflammatory responses in the future(13). Our study may appear to challenge the 454 
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concept that antigen-specific immunization is more successful in the presence of an adjuvant 455 
that is designed to increase inflammatory responses. However while adjuvants may enhance 456 
the induction of immunity in draining lymph nodes, excessive inflammation that is present at the 457 
site of the effector phase of a response may inhibit T cell responsiveness. This may be a 458 
mechanism to protect against pathology induced by excessive immune stimulation in the 459 
tissues.  Furthermore excessive inflammation is detrimental for cancer progression(49) and the 460 
temporary inhibition of inflammation in this situation may be a strategy for boosting 461 
immunotherapy in these patients. While the current challenge is to identify the optimal way to 462 
reduce excessive inflammation and to enhance immunity in ageing humans, it is serendipitous 463 
that some drugs that may do this have already been developed and may therefore be 464 
repurposed.  465 
   466 
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Figure Legends 
 
Figure 1. Cutaneous response to Varicella Zoster Virus (VZV) antigen is reduced in old 
individuals 
Healthy young and old volunteers were injected VZV skin antigen test ( female =circles and  male 
= diamonds). A clinical score at day 3 in response to VZV, was calculated based on induration, 
palpability and redness. (A) Clinical score versus participant’s age. (B) Haematoxylin and eosin 
staining (x10), PV, perivascular infiltrates 5mm punch biopsies were performed on days 0, 1, 3 or 
7 post injection (with 4-7 volunteers per timepoint. (C) Representative skin sections stained for 
CD4 (green) (original magnification: x400).  (D) Collated data of T cell numbers at different times 
after VZV injection in young and old volunteers. Each symbol represents the average number of 
CD4+ T cells within perivascular infiltrates for each individual (n=4-7 per time point; Mann 
Whitney test, horizontal bar represent the mean). (E) Clinical score at 48 h (peak clinical 
response) correlated with the number of CD4+ T cells in the perivascular infiltrate at the peak of 
cellular response on day 7 (n=10 young [black circles] and 22 old [white circles]).  * = p<0.05, ** = 
p<0.01, *** = p<0.001. 
 
Figure 2. Perivascular cluster formation is reduced in the skin of old individuals.  
5 mm punch biopsies were performed on days 0, 1, 3 or 7 post- VZV injection (with 3-6 
volunteers per time point). (A) Representative staining of skin sections immunostained for CD11c 
(original magnification x10). (B) Cumulative data showing mean CD11c+ cell number per field 
(young - filled bars, old- open bars). Data shown as mean ± SEM. * = p<0.05, ** = p<0.01. (C) 
Representative staining showing CD11c+ DC (red) and CD4+ T cells (green) in a perivascular 
cluster (representative young donor, day 3 after VZV injection,  x400).   
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Figure 3. Transcriptomic analysis of young and old skin after VZV antigen challenge. 
3mm punch biopsies were collected from old (n=10) and young individuals (n=6) at 6 and 72 h 
post-VZV injection. Normal skin punch biopsies were collected from and additional group of 
young (n=9) and old individuals (n=6). Total skin RNA was isolated, amplified and hybridized to 
Affymetrix Human Genome U133 2.0 plus arrays. (A) Heatmap showing the relative expression 
of differentially expressed genes between VZV injected and normal skin in young (left panel) and 
old (right panel) at FCH>2 and FDR>0.05 in normal/unmanipulated skin, 6 hours post-VZV  and 
72 hours post-VZV challenged skin in each grouup. For each gene, only the probeset with the 
largest average expression is shown. Unsupervised clustering was carried out using Pearson 
correlation distance with Mcquitty agglomeration scheme of DEG at 6 h following VZV.  (B) Table 
shows top 30 up-regulated genes at 72h in young and old subjects compared to normal skin in 
each group. 
 
Figure 4.  Comparison of global gene expression between normal, saline-injected and VZV 
antigen-injected skin.   
(A) Schematic representation of biopsy collection for transcriptional analysis. (B). Heatmap 
showing the relative expression of DEG (FCH>2 and FDR>0.05) between normal skin and 
saline-injected skin at 6 hours after treatment in young (left panel) and old (right panel) 
individuals.  (C) Table showing the top 20 upregulated genes at 6 hours in the saline-injected old 
and young skin compared to normal skin.  Genes not reaching statistical significance are 
indicated in blue. Asterisk indicates genes related to p38 MAP kinase signalling. (D) Bubble plot 
shows expression of pathways in saline-injected skin versus normal skin. KEGG and GO 
collection, as well as a curated skin-related collection were interrogated and the most relevant 
pathways amongst them with FDR<0.05 are presented. (E) Inflammatory index was calculated 
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for each individual (see methods) and plotted against VZV clinical score at 72 hours (young n=6 
and old n=10). 
Figure 5 Identification of a monocyte/macrophage-related gene expression signature in 
saline-injected aged skin.  
(A) Transcriptomic analysis using the tool Biolayout Express3D  of the genes upregulated in the 
skin of elderly humans 6 hours after saline treatment which clusters together in a large network of 
monocyte/macrophage-related genes (C_, cluster no.; nodes represent individual genes; edges 
represent Pearson correlations >0.7). (B) representative images of CD163 stained saline-injected 
skin from young and old and (C) cumulative data of CD163+ cells in paired analysis from normal 
and saline injected skin at 6 hours individuals (n=4-5 per age group).  (D) The frequency of 
mononuclear phagocytes determined as being CD45+ Lineage- (CD3-, CD19-, CD20- and CD56-) 
and  HLA-DR+ and either CD14+ and/or CD16+, expressed as a % of CD45+ lineage negative, in 
young (white) and old (black) pre- and post-saline as assessed by flow cytometry.  Data 
assessed by paired t-test.  
 
Figure 6. Effects of Losmapimod treatment on VZV response in the skin.  
(A). Responses to VZV skin challenge were investigated in old individuals (n=18, 8M, 10F) pre- 
and post-Losmapimod treatment  (15 mg twice daily for 4 days). (B) Serum CRP levels before 
pre- and post-Losmapimod treatment (n=18, p=0.04, Wilcoxon paired test). (C) Whole blood LPS 
stimulation was performed pre- and post-Losmapimod treatment, and TNF-α production 
measured by CBA (LPS p<0.0001, Losmapimod p<0.0001, Two way ANOVA n=18). (D) Clinical 
score was measured at 48 hrs after VZV antigen challenge pre and post Losmapimod (p=0.0006, 
Wilcoxon  paired test, red symbol indicates the mean). (E) Correlation between change in serum 
CRP and change in clinical score after Losmapimod treatment (Pearson correlation). (F) 
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Representative images of skin sections collected 7 days post-VZV injection, stained for CD4 
(red) and CD11c (pale blue) pre- and post-Losmapimod treatment in one of the individuals who 
showed an increased clinical score in response to VZV improved after Losmapimod treatment 
(top and bottom right panels) and one of individuals whose clinical score remained low following 
Losmapimod treatment (top and bottom left panels).  White arrows indicate a dendritic cell 
interacting with surrounding T cells. 
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List of Supplementary material:  
Tables:  
Supplementary Table 1. Information on age, gender and clinical score of participants 
recruited into the study  
Supplementary table 2.  Detailed information on gender and clinical score of 
participants recruited into the study. 
Supplementary Table 3: Antibodies used in immunohistochemistry 
Supplementary Table 4: Antibodies used in immunofluorescence 
Supplementary Table 5: Antibodies used for Flow-cytometric analysis 
Supplementary Table 6.  VZV injected vs normal skin differentially expressed genes  
Supplementary Table 7. Saline injected vs normal skin differentially expressed genes 
Supplementary Table 8. List of 384 genes (positive regulators of inflammation) used 
in the inflammatory index 
Supplementary table 9. Contents of clusters described in Fig 5A. 
Figures: 
Supplementary Figure 1. Clinical response to VZV antigen challenge in different age 
groups. 
Supplementary Figure 2. Phenotype of CD4 and CD8 T cells resident in normal skin 
of young and old individuals. 
Supplementary figure 3. Proliferation of CD8 T cells following VZV antigen challenge 
is reduced in the old. 
Supplementary Figure 4. Activation of dermal endothelium at site of VZV challenge  
Supplementary Figure 5. Pathway analysis of gene expression in young and old skin 
at 6 and 72 h post VZV antigen challenge. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 Supplementary Figure 6. Overlap of differentially expressed genes (DEG) in the skin 
of young and old individuals in the skin after injection of saline or VZV antigen. 
Supplementary Figure 7. Inflammatory response induced by saline injection inversely 
correlates with the response to VZV antigen challenge 
Supplementary Figure 8. Saline injection increases the frequency of HLA-DR+ cells 
and mononuclear phagocytes in old but not young individuals.   
Supplementary figure 9. Repeat skin testing with VZV skin antigen does not affect 
the clinical response in old individuals. 
Supplementary Figure 10. Effect of Losmapimod treatment on immune function 
 
Supplementary text: 
Methods:  
Participant exclusion criteria: Individuals with history of neoplasia, 
immunosuppressive disorders or inflammatory skin disorders were excluded from 
this investigation. Furthermore, we excluded individuals with co-morbidities that are 
associated with significant internal organ or immune dysfunction including heart 
failure, severe COPD, diabetes mellitus and rheumatoid arthritis and individuals on 
immunosuppressive regimes for the treatment of autoimmune or chronic 
inflammatory diseases (e.g. oral glucocorticoids, methotrexate, azathioprine and 
cyclosporin). We did not exclude volunteers with a history of uncomplicated 
hypertension or hypercholesterolaemia as this would have prevented the majority of 
ageing volunteers from participating in this study. The blood pressure and cholesterol 
level were not specifically measured for each volunteer, but those volunteers taking 
medication for a previously confirmed diagnosis of hypertension or 
hypercholesterolaemia were identified. 
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PBMC stimulation: PBMCs were isolated as standard and then subsequently stored 
at -80oC. The PBMCs were defrosted, counted and then cultured overnight at 5x105 
cells/ml with plate bound anti-CD3 (1µg/ml) and IL-2 (50IU/ml) for eighteen hours at 
37oC with 5% CO2. Brefeldin A (5µg/ml) was added two hours into the incubation. 
The cells were removed and cell surface stained with the following antibodies CD3, 
CD4, CD8 (clones UCHT1, SK3, SK9 respectively; BD) and Live/Dead after two 
washed the cells were fixed and permeabilised in Foxp3 staining buffers (as per the 
manufacturer’s instructions; eBiosciences) and intracellularly stained with the 
following antibodies: IFNγ, IL-2, TNFα and Ki67 (clones 4S.B3, MQ1-17H12, Mab11 
and Ki-67 respectively; Biolegend. Samples were acquired on the BD Symphony (BD 
Biosciences) and were subsequently analysed using FLowJo Version X (Treestar). 
Transcriptional analysis of skin biopsies: Target amplification and labelling was 
performed according to standard protocols using Nugen Ovation WB Kit.  RNA was 
hybridized to Affymetrix Human Genome U133 2.0 plus arrays. Affymetrix gene chips 
were scanned for spatial artefacts using the Hirshlight package50. Gene expression 
measures were obtained using the GCRMA algorithm51 and was modelled using 
mixed-models in R’s limma framework. Differences between groups were estimated 
from this model and its significance assessed using the moderated (paired/unpaired) 
t-test. Resulting P-values were adjusted for multiple hypotheses using the Benjamini-
Hochberg procedure. Gene set variation analysis (GSVA)52 was used to obtained the 
per-pathway scores for each patient and sample; using a collection of skin-specific 
pathways curated by the Krueger lab.  
Network analysis of the genes expressed within skin biopsies was performed as 
described19. Briefly, normalized, nonlog-transformed, annotated, gene-expression 
data were imported into BioLayout Express3D (www.biolayout.org), a tool designed 
specifically for the visualization of large gene-expression network graphs53.  Network 
graphs were then created using a Pearson correlation coefficient cut-off threshold of 
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r = 0.95. Each network graph was then clustered into groups of genes sharing similar 
profiles using the Markov clustering algorithm. The graphs were then explored to 
understand the biological significance of the gene clusters, identify those expressed 
by the young and old skin samples and their functional relationships to the other cell 
populations represented.   
 
Figure legends: 
Supplementary Figure 1.  Effect of age on clinical response to intradermal 
injection of VZV antigen. Healthy young and old volunteers were injected with 0.02 
ml VZV skin test antigen and  clinical score based on a combination of extent of 
induration, palpability and redness at the injection site was measured  at day  3 post 
challenge. Volunteers were split into age groups and mean, median and range f 
clinical scores calculated (A). Graph shows mean ± SEM for each age group. Mann-
Whitney test was used to compare changes between age groups 
.Supplementary Figure 2. Phenotype of CD4 and CD8 T cells resident in normal 
skin of young and old individuals. Sections of normal skin were immunostained to 
detect CD4, CD8, CD69, CD103 using an indirect immunofluorescence method. (A). 
Representative image of normal skin immunostained for CD4 (green), CD69 (red) 
and CD103 (white). (B) The proportion of CD4+ cells expressing CD69 in young and 
old skin (n=11). (C) The proportion of CD4+CD69+ cells expressing CD103 in young 
and old skin (n=10). (D) The proportion of CD8+ cells expressing CD69 in young and 
old skin (n=11). (E) The proportion of CD8+CD69+ cells expressing CD103 in young 
and old skin (n=10).  For B-E the line indicates the mean. 
Supplementary Figure 3. Proliferation of T cells following VZV antigen 
challenge is reduced in the old.   (A) Representative immunostaining of ki67 
expression in skin afterday 3 and 7 post-VZV injection (Ki67 green; CD4 red). (B) 
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Cumulative data showing the frequency of CD4+ cells expressing Ki67 per 
perivascular infiltrate (young - filled bars, old- open bars).  (C) Representative 
immunostaining on days 3 and 7 post-injection: Ki67 (green) and CD8 (red). (D) 
Cumulative data of the percentage of CD8+ cells expressing Ki67 per perivascular 
infiltrate in each donor. Data shown as mean ± SEM. * = p<0.05, ** = p<0.01, *** = 
p<0.001. 
Supplementary Figure 4. Activation of dermal endothelium at site of VZV 
challenge Immunofluorescence staining for CD31 and E-selectin or VCAm1 
expression was performed on skin sections from biopsies taken from normal skin and 
6 h, day 1 and day 3 after cutaneous challenge with VZV antigen from young and old 
volunteers (n=4-5 per age group at each time point). The number of double positive 
staining vessels expressed as a proportion of the total number of vessels in the 
superficial and mid-dermis of each section was used for analysis for each individual. 
(A) Representative images are shown CD31 (green) and E-selectin (red). (B) 
cumulative data (p values indicated, Mann Whitney test). (C) Expression of  VCAM1 
on CD31+ capillary loops 6hrs after VZV injection. (D) Healthy young and old 
volunteers (n=5) were injected with 0.02 ml VZV skin antigen test and 5 mm punch 
biopsies were performed 6hrs post injection.  Skin sections were immunostained with 
CD11c, CD4 and neutrophil elastase and the number of positive cells was counted 
per field. For B-D data shown as mean ± SEM. (E) Normal and VZV (6 hours post-
injection) paired skin biopsies were assessed for mononuclear phagocyte numbers 
by immunofluorescence staining utilising HLA-DR, CD14 and CD16. Any cell that 
was HLA-DR+ and CD14+ and/or CD16+ was defined as being a mononuclear 
phagocyte, analysis was performed in young (black, n=5) and old (white, n=5). For E 
data was assessed by a paired t-test * = p<0.05..  
Supplementary Figure 5. Pathway analysis of gene expression in young and 
old skin at 6 and 72 h post VZV antigen challenge . Differentially expressed genes 
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between VZV injected and normal skin in young or old at FCH>2 and FDR>0.05. 
Unsupervised clustering was carried out using Pearson correlation distance with 
Mcquitty agglomeration scheme. (A) Venn diagrams show numbers of DEG at 6 h 
following VZV antigen injection compared to normal skin. Up-regulated genes are 
shown in red, down-regulated genes in blue. (B) Table shows top 30 up-regulated 
genes at 6 h in young, genes not significantly up-regulated in old skin are indicated in 
bold italics. (C). Bubble plot representing the overall representation of relative gene 
expression in VZV-injected skin versus normal skin. KEGG and GO collection, as 
well as a curated skin-related collection were interrogated and the most relevant 
pathways amongst them with FDR<0.05 are presented.  The area of each circle is 
proportional to the differences in the GSVA-derived pathway scores between VZV-
injected and normal skin in each group. Colours indicate the direction of 
dysregulation red (up) and blue (down).  Colour intensity represents the strength of 
the dysregulation determined by FDR. 
Supplementary Figure 6. Overlap of differentially expressed of genes (DEG) in 
the skin of young and old individuals in the skin after injection of saline or VZV 
antigen. A selection of differentially expressed genes of interest are indicated for 
each (red, up-regulated and blue, down-regulated). (B) Principal component analysis 
of global gene expression in normal skin and 6 h after injection with saline or VZV 
antigen. (C) Table shows top 30 up-regulated genes at 6 h in saline and VZV injected 
skin. 
Supplementary Figure 7. Inflammatory response induced by saline injection 
inversely correlates with the response to VZV antigen challenge.  The 
expression of individual inflammatory genes in the skin 6 h after saline was 
compared by qRT-PCR analysis and plotted against the clinical score following VZV 
antigen injection at 48 hours. 
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Supplementary Figure 8. Frequency of HLA-DR+ cells and mononuclear 
phagocytes following saline injection 5mm punch biopsies were collected from 
normal or injected skin and digested overnight to provide single cell suspension. (A) 
Gating strategy employed to identify mononuclear phagocytes and dendritic cells in 
human skin; CD45+ lineage cocktail negative single cells were identified, 
subsequently, HLA-DR+ CD14+ and/or CD16+ were mononuclear phagocytes and 
HLA-DR+CD14-CD16-  were dendritic cells (DCs) either CD141+ or CD11c+ DCs. (B) 
cumulative data of mononuclear phagocyte populations 24 hours post-saline 
injection. (C) Phenotype of mononuclear phagocytes in the young and old donors 
(CD14+CD16- grey, CD14+CD16+ white, CD16+CD14- black). * = p<0.05 
Supplementary figure 9. Repeat skin testing with VZV skin antigen does not 
affect the clinical response in old individuals. 14 individuals with clinical score 
below 4 were re-challenged with VZV in the skin 2-5 months after the original skin 
test. Clinical score for both skin tests are shown in the table (p>0.5).  
Supplementary figure 10. Effect of Losmapimod treatment on immune 
functionA). Whole blood LPS stimulation was performed pre- and post-Losmapimod 
treatment in the same donors, and IL-6 and IL-8 was production measured by CBA 
(LPS p<0.0001, Losmapimod p<0.0001, Two way ANOVA n=18). PBMCs were 
stimulated overnight with CD3 and IL-2 were assessed by flow cytometric analysis in 
CD4+ T cells (B) for intracellular cytokine expression and (C) Ki67 expression and 
additionally in CD8 T cells (D) for intracellular cytokine expression and (E) Ki67 
expression pre- and post-losmapimod treatment (white circles and black squares 
respectively). Figure B-E were assessed by a paired t-test and no significant 
difference was observed.  
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 Old female Old male Young female Young male  
number 47 31 56 41 
Age range 65-93 65-93 20-39 20-39 
Average age 75.7 77.5 28.3 29.6 
Median age 74 77 29 29 
Score range 0-8 0-6 0-9 0-9 
Mean score 2.3 1.9 5.5 5.5 
Median score 2 1 5 6 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Supplementary Table 2: 
 young middle old 
number 97 14 78 
Age range 20-39 41-64 65-93 
Median age 29 52 75.5 
Gender  56F/41M 8F/6M 47F/31M 
Score range 0-9 0-7 0-8 
Mean score 5.5 4.5 2.18 
Median score 6 5 2 
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Supplementary Table 3: 
 
 
 
 
 
 
 
 
Antibody name Clone Company 
CD11c B-ly6 BD Bioscience 
CD4 SK3 BD Bioscience 
CD163 5C6-FAT Acris 
DC-LAMP 104.G4 Beckman Coulter 
Neutrophil elastase NP75 Dako 
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Supplementary Table 3: 
Antibody name Clone Company 
CD4 SK3 or YNB46.1.8 BD Bioscience 
CD8 RPA-T8 BD Bioscience 
Ki67 - FITC B56 BD Bioscience 
CD31 - FITC WM59 BD Bioscience 
CD11c B-ly6 BD Bioscience 
Ki67 - FITC B56 BD Bioscience 
CD69 FN50 Biolegend 
CD103 2G5.1 Thermofisher 
Foxp3 - Biotin PCH101 eBioscience 
PD-1 NAT105 Abcam 
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 E-selectin ENA1 Abcam 
CD163 RM3/1 Abcam 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Antibody name Clone Company 
CD11c 3.9 Biolegend 
CD14 HCD14 Biolegend 
CD16 3G8 Biolegend 
CD19 HIB19 Biolegend 
CD20 2H7 Biolegend 
CD56 HCD56 Biolegend 
CD163 GHI/61 Biolegend 
HLA-DR 104.G4 BD Biosciences 
CD3 UCHT1 BD Biosciences 
CD45 2D1 BD Biosciences 
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117_at 0.93 1.91 0.0275 0.0616 0 0.35 1.28 0.399
1294_at 2.01 4.02 6.27E-07 7.08E-06 1 -0.85 -1.8 0.0233
1316_at -0.89 -1.86 0.00755 0.021 0 -1.21 -2.31 0.000401
1405_i_at 5.92 60.73 1.67E-07 2.30E-06 1 0.18 1.13 0.861
1438_at -1.83 -3.56 3.25E-07 4.05E-06 -1 -0.55 -1.46 0.0963
1552256_a_at -1.41 -2.66 8.26E-07 8.95E-06 -1 -0.4 -1.32 0.134
1552263_at 1.43 2.7 7.78E-05 0.000416 1 0.16 1.11 0.65
1552264_a_at 1.18 2.26 1.79E-05 0.000118 1 0.47 1.39 0.0678
1552283_s_at -1.35 -2.54 0.0093 0.025 -1 -0.69 -1.62 0.173
1552286_at -1.24 -2.36 2.20E-06 2.03E-05 -1 -0.76 -1.69 0.00243
1552302_at 2.4 5.28 2.08E-09 6.28E-08 1 0.74 1.67 0.0371
1552303_a_at 2.32 4.98 1.36E-12 2.37E-10 1 0.43 1.35 0.115
1552316_a_at 2.98 7.89 4.59E-09 1.18E-07 1 -0.32 -1.25 0.479
1552318_at 2.33 5.03 4.84E-06 3.94E-05 1 -0.94 -1.92 0.0483
1552320_a_at 4.5 22.67 7.06E-11 4.61E-09 1 0.47 1.38 0.427
1552323_s_at 1.04 2.05 0.00937 0.0252 1 -1.4 -2.64 0.000579
1552327_at -2.1 -4.29 8.29E-09 1.94E-07 -1 -1.83 -3.55 2.67E-07
1552343_s_at 1.99 3.98 8.90E-06 6.59E-05 1 -0.54 -1.46 0.197
1552344_s_at 1.29 2.45 1.39E-06 1.39E-05 1 1.07 2.1 4.08E-05
1552365_at -1.53 -2.88 6.04E-05 0.000334 -1 -0.29 -1.22 0.422
1552367_a_at -1.43 -2.69 0.000795 0.00307 -1 -0.22 -1.17 0.588
1552398_a_at 2.57 5.93 0.00971 0.0259 1 0.36 1.29 0.707
1552400_a_at -0.36 -1.28 0.421 0.545 0 -1.8 -3.49 0.00011
1552474_a_at -1.01 -2.02 0.000301 0.00133 -1 -0.72 -1.65 0.00848
1552480_s_at 4.8 27.87 8.41E-10 3.11E-08 1 0.66 1.58 0.335
1552482_at -1.18 -2.27 0.00039 0.00166 -1 -0.47 -1.38 0.144
1552485_at 1.33 2.52 0.000143 0.000702 1 1 2 0.00345
1552486_s_at 1.61 3.05 1.08E-06 1.12E-05 1 1.16 2.23 0.000271
1552487_a_at -0.47 -1.39 0.162 0.261 0 1.44 2.71 5.33E-05
1552491_at 0.01 1.01 0.975 0.984 0 1.33 2.51 9.99E-06
1552496_a_at -1.43 -2.69 3.85E-07 4.67E-06 -1 -0.35 -1.27 0.176
1552497_a_at 6.2 73.51 3.24E-11 2.55E-09 1 0.26 1.2 0.743
1552502_s_at -1.19 -2.29 0.00142 0.00503 -1 0.01 1.01 0.981
1552509_a_at -2.25 -4.77 7.50E-05 0.000402 -1 -0.88 -1.85 0.103
1552532_a_at -1.15 -2.23 3.82E-07 4.65E-06 -1 -0.12 -1.09 0.562
1552553_a_at 2.85 7.19 7.98E-09 1.88E-07 1 0.95 1.93 0.0321
1552562_at 0.33 1.26 0.148 0.243 0 1.01 2.01 3.72E-05
1552566_at -1.54 -2.9 0.00148 0.00522 -1 0.52 1.43 0.267
1552575_a_at -3.54 -11.64 7.78E-12 8.67E-10 -1 -0.93 -1.9 0.0354
1552584_at 4.63 24.75 3.45E-10 1.57E-08 1 0.53 1.44 0.408
1552612_at 2.69 6.45 2.08E-07 2.78E-06 1 0.16 1.11 0.74
1552613_s_at 2.44 5.42 9.23E-10 3.32E-08 1 0.27 1.21 0.436
1552618_at 1.04 2.06 0.0146 0.0365 1 0.66 1.58 0.115
1552619_a_at -1.2 -2.29 0.0103 0.0271 -1 -1.38 -2.6 0.00332
1552626_a_at 1.41 2.66 1.89E-06 1.79E-05 1 0.48 1.4 0.0809
1552633_at 2.14 4.41 2.50E-10 1.24E-08 1 0.13 1.09 0.655
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117_at -0.34 -1.26 0.417 1 0 -0.14 -1.1 0.734
1552487_a_at -0.01 -1.01 0.975 1 0 0.91 1.88 0.00797
1552491_at -0.16 -1.12 0.56 1 0 0.7 1.62 0.0147
1552641_s_at -0.25 -1.19 0.556 1 0 0.31 1.24 0.465
1553749_at -0.05 -1.04 0.818 1 0 0.47 1.38 0.0366
1553787_at -0.24 -1.18 0.557 1 0 -0.96 -1.95 0.0201
1553789_a_at -0.26 -1.2 0.455 1 0 -0.9 -1.87 0.0106
1553861_at 0.17 1.12 0.702 1 0 0.38 1.3 0.382
1554008_at 0.22 1.16 0.543 1 0 1.42 2.69 0.000145
1554283_at 0.04 1.03 0.902 1 0 0.8 1.74 0.0133
1554406_a_at 0.47 1.38 0.55 1 0 0.21 1.16 0.789
1554704_at -0.45 -1.36 0.192 1 0 -1.6 -3.04 1.09E-05
1554748_at 0.06 1.04 0.914 1 0 -0.08 -1.06 0.882
1554834_a_at 0.42 1.34 0.458 1 0 0.85 1.81 0.136
1555131_a_at 0.25 1.19 0.499 1 0 -1.23 -2.34 0.00163
1555167_s_at -0.41 -1.33 0.488 1 0 1.36 2.56 0.0252
1555318_at -0.35 -1.28 0.608 1 0 -1.83 -3.56 0.00906
1555427_s_at 0.06 1.04 0.881 1 0 0.7 1.63 0.0637
1555600_s_at 0.64 1.55 0.294 1 0 1 1.99 0.103
1555638_a_at 0.17 1.12 0.85 1 0 0.1 1.07 0.915
1555756_a_at 0.45 1.37 0.555 1 0 0.3 1.23 0.692
1555760_a_at -0.43 -1.34 0.354 1 0 0.14 1.11 0.752
1555870_at 0.36 1.28 0.394 1 0 -0.63 -1.55 0.134
1556069_s_at -0.39 -1.31 0.537 1 0 -0.23 -1.17 0.717
1556081_at -0.54 -1.45 0.0793 1 0 0.46 1.37 0.136
1556185_a_at -0.34 -1.27 0.356 1 0 0.14 1.1 0.715
1556210_at -0.36 -1.29 0.387 1 0 -1.42 -2.67 0.00116
1556211_a_at -0.18 -1.13 0.639 1 0 -1.02 -2.02 0.00843
1556212_x_at -0.03 -1.02 0.944 1 0 -0.9 -1.87 0.0204
1556253_s_at 0.52 1.43 0.264 1 0 -0.07 -1.05 0.876
1556300_s_at -1.38 -2.61 0.0126 1 0 0.21 1.16 0.7
1556321_a_at -0.35 -1.28 0.313 1 0 0.67 1.59 0.059
1556361_s_at -0.26 -1.2 0.541 1 0 0.81 1.75 0.0592
1556385_at 0.07 1.05 0.911 1 0 1.2 2.3 0.0465
1556402_at -0.45 -1.37 0.26 1 0 -0.61 -1.52 0.13
1556579_s_at 0.3 1.23 0.512 1 0 -0.03 -1.02 0.939
1556589_at -0.15 -1.11 0.74 1 0 -1.08 -2.12 0.0185
1556590_s_at -0.06 -1.04 0.91 1 0 -0.82 -1.76 0.115
1556758_at -0.43 -1.34 0.186 1 0 0.16 1.12 0.617
1556770_a_at -0.31 -1.24 0.537 1 0 -1.07 -2.09 0.0363
1556867_at -0.04 -1.03 0.931 1 0 1.55 2.93 0.00148
1556989_at -0.83 -1.78 0.168 1 0 0.35 1.28 0.554
1557155_a_at 1.22 2.33 0.00354 1 0 1.23 2.34 0.0033
1557383_a_at -0.26 -1.2 0.578 1 0 -1.42 -2.68 0.00346
1557458_s_at 0.2 1.15 0.57 1 0 0.7 1.63 0.0491
1557553_at 0.18 1.13 0.779 1 0 -0.18 -1.14 0.767
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PositiveRegulators
ABCB9
ADAM10
ADAM17
ADAM8
ADK
ADORA2B
AIF1
AKT1
AP3B1
AP3D1
AQP3
ATF1
ATF2
AXL
BAD
BCAR1
BCL10
BCL2
BDKRB1
BIRC2
BIRC3
BLM
BLOC1S3
BMI1
BTK
C1QA
C1QB
C1QC
C1R
C1RL
C1S
C2
C3
C3AR1
C4BPB
C6
C7
CACNB3
CADM1
CAMK1D
CARD11
CARD9
CASP8
CAV1
CCL19
CCL21
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Gene symbol:probe set IDSymbol DescriptionID EntrezID Chrom ChromLoc PathwayID PathDesc
BID;211725_s_atBID BH3 interacting domain death agonist211725_s_at 637 22 18216905 04115, 04210, 04650, 05010, 05014, 05200, 05416p53 signaling pathway, Apoptosis, Natural killer cell mediated cytotoxicity, Alzheimer s disease, Amyotrophic lateral sclerosis (ALS), Pathways in cancer, Viral myocarditis
C1orf38;207571_x_atC1orf38 chromosome 1 open reading frame 38207571_x_at 9473 1 28199054 - -
C1orf38;210785_s_atC1orf38 chromosome 1 open reading frame 38210785_s_at 9473 1 28199054 - -
C5AR1;220088_atC5AR1 complement component 5a receptor 1220088_at 728 19 47813103 04080, 04610Neuroactive ligand-receptor interaction, Complement and coagulation cascades
CCR1;205098_atCCR1 chemokine (C-C motif) receptor 1205098_at 1230 3 46243199 04060, 04062Cytokine-cytokine receptor interaction, Chemokine signaling pathway
CCR1;205099_s_atCCR1 chemokine (C-C motif) receptor 1205099_s_at 1230 3 46243199 04060, 04062Cytokine-cytokine receptor interaction, Chemokine signaling pathway
CD300A;209933_s_atCD300A CD300a molecule209933_s_at 11314 17 72462521 - -
CHST11;226368_atCHST11 carbohydrate (chondroitin 4) sulfotransferase 11226368_at 50515 12 1.05E+08 00532, 00920Chondroitin sulfate biosynthesis, Sulfur metabolism
CHST11;226372_atCHST11 carbohydrate (chondroitin 4) sulfotransferase 11226372_at 50515 12 1.05E+08 00532, 00920Chondroitin sulfate biosynthesis, Sulfur metabolism
CLEC4E;222934_s_atCLEC4E C-type lectin domain family 4, member E222934_s_at 26253 12 8685900 - -
CLEC7A;1554406_a_atCLEC7A C-type lectin domain family 7, member A1554406_ _at 64581 12 10269375; 10279923- -
CLEC7A;1555756_a_atCLEC7A C-type lectin domain family 7, member A1555756_ _at 64581 12 10269375; 10279923- -
CLEC7A;221698_s_atCLEC7A C-type lectin domain family 7, member A221698_s_at 64581 12 10269375; 10279923- -
CSF2RB;205159_atCSF2RB colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)205159_at 1439 22 37309674 04060, 04210, 04630Cyt kine-cytokine receptor interaction, Apoptosis, Jak-STAT signaling pathway
CTSS;202902_s_atCTSS cathepsin S202902_s_at 1520 1 1.51E+08 04142, 04612Lysosome, Antigen processing and presentation
CYBB;203923_s_atCYBB cytochrome b-245, beta polypeptide203923_s_ t 1536 X 37639269 4670 Leukocyte transendothelial migration
CYTH4;219183_s_atCYTH4 cytohesin 4219183_s_at 27128 22 37678494 - -
DOK3;223553_s_atDOK3 docking protein 3223553_s_at 79930 5 176928914; 176930751- -
EFHD2;222483_atEFHD2 EF-hand domain family, member D2222483_at 79180 1 15736390 - -
EMR2;207610_s_atEMR2 egf-like module containing, mucin-like, hormone receptor-like 2207610_s_at 30817 19 14843204 - -
FCGR2A;203561_atFCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32)203561_at 2212 1 1.61E+08 04666, 05322Fc gamma R-mediated phagocytosis, Systemic lupus erythematosus
FGR;208438_s_atFGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog208438_s_at 2268 1 27938802 4062 Chemokine signaling pathway
HCK;208018_s_atHCK hemopoietic cell kinase208018_s_at 3055 20 30639990 04062, 04666Chemokine signaling pathway, Fc gamma R-mediated phagocytosis
IGSF6;206420_atIGSF6 immunoglobulin superfamily, member 6206420_at 10261 16 21652605 - -
ITGAX;210184_atITGAX integrin, alpha X (complement component 3 receptor 4 subunit)210184_at 3687 16 31366508 4810 Regulation of actin cytoskeleton
LILRA2;207857_atLILRA2 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2207857_at 11027 19 55085256 - -
LILRA2;211100_x_atLILRA2 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2211100_x_at 11027 19 55085256 - -
LILRA2;211101_x_atLILRA2 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2211101_x_at 11027 19 55085256 - -
LILRB1;211336_x_atLILRB1 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1211336_x_at 10859 19 55128628; 55141907; 55141967- -
LILRB1;229937_x_atLILRB1 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1229937_x_at 10859 19 55128628; 55141907; 55141967- -
LILRB2;207697_x_atLILRB2 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2207697_x_at 10288 19 54777675 - -
LILRB2;210146_x_atLILRB2 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2210146_x_at 10288 19 54777675 - -
LILRB3;211135_x_atLILRB3 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3211135_x_at 11025 19 54720146 4662 B cell receptor signaling pathway
LYN;202625_atLYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolog202625_ t 4067 8 56792385 04062, 04662, 04664, 04666, 04730, 05120Chemokine signaling pathway, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term depression, Epithelial cell signaling in Helicobacter pylori infection
LYN;202626_s_atLYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolog202626_s_at 4067 8 56792385 04062, 04662, 04664, 04666, 04730, 05120Chemokine signaling pathway, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term depression, Epithelial cell signaling in Helicobacter pylori infection
LYN;210754_s_atLYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolog210754_s_at 4067 8 56792385 04062, 04662, 04664, 04666, 04730, 05120Chemokine signaling pathway, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term depression, Epithelial cell signaling in Helicobacter pylori infection
LYZ;1555745_a_atLYZ lysozyme (renal amyloidosis)1555745_a_at 4069 12 69742133 - -
NA;204961_s_atNA NA 204961_s_atNA - - - -
NA;210225_x_atNA NA 210225_x_atNA - - - -
NA;210784_x_atNA NA 210784_x_atNA - - - -
NA;211133_x_atNA NA 211133_x_atNA - - - -
NA;227184_atNA NA 227184_at NA - - - -
NA;228685_atNA NA 228685_at NA - - - -
NADK;213607_x_atNADK NAD kinase213607_x_at 65220 1 1682677 00760, 01100Nicotinate and nicotinamide metabolism, Metabolic pathways
PILRA;219788_atPILRA paired immunoglobin-like type 2 receptor alpha219788_at 29992 7 99971067 - -
PILRA;222218_s_atPILRA paired immunoglobin-like type 2 receptor alpha222218_s_at 29992 7 99971067 - -
PTAFR;206278_atPTAFR platelet-activating factor receptor206278_a 5724 1 28473677 04020, 04080Calcium signaling pathway, Neuroactive ligand-receptor interaction
PTAFR;211661_x_atPTAFR platelet-activating factor receptor211661_x_at 5724 1 28473677 04020, 04080Calcium signaling pathway, Neuroactive ligand-receptor interaction
PTPRE;221840_atPTPRE protein tyrosine phosphatase, receptor type, E221840_at 5791 10 129705324; 129845812- -
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